The FDA approved a new strength of a trastuzumab biosimilar; UnitedHealth will remove reference adalimumab from some ...
In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...
Otulfi was approved simultaneously in the European Union. In the US, it will launch in February 2025.
A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford ...
Number 1: Amgen’s Pavblu (aflibercept-ayyh) is the fifth biosimilar referencing Eylea (aflibercept) to be approved for ...
The European Commission (EC) approved Celltrion's ustekinumab biosimilar for chronic inflammatory diseases, Celltrion ...
The article by Sarfaraz K. Niazi, PhD, critiques the irrationality surrounding biosimilars, suggesting that regulatory ...
Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics ...
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote ...
The Inflation Reduction Act (IRA) has modestly boosted oncology biosimilar uptake through Medicare reimbursement, but its ...
An observational study assessing patient satisfaction with adalimumab for inflammatory bowel disease (IBD) reported a high ...
Ivo Abraham, PhD, RN, University of Arizona Cancer Center, explains how biosimilars are becoming more accessible but face challenges like price erosion and potential shortages.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback